Baudax Bio Inc
Change company Symbol lookup
Select an option...
BXRX Baudax Bio Inc
ZM Zoom Video Communications Inc
CIOXY Cielo SA
T AT&T Inc
PBCT People's United Financial Inc
PHK PIMCO High Income Fund
BAC Bank of America Corp
BHF Brighthouse Financial Inc
CTBI Community Trust Bancorp Inc
$NYLGCAPT NYSE U.S. Large Cap Equal Weight Ind
Go

Company profile

Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.

Price
Delayed
$3.82
Day's Change
0.13 (3.52%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.85
Day's Low
3.69
Volume
(Light)

Today's volume of 192,245 shares is on pace to be much lighter than BXRX's 10-day average volume of 982,021 shares.

192,245

Tesla target cut at Citi due to risks of extended Fremont shutdown

8:07 am ET March 24, 2020 (MarketWatch)
Print

Citi analyst Itay Michaeli lowered his price target on Tesla Inc. shares (TSLA) to $246 from $312 Tuesday, writing that he is increasing the probability of the bear case in his scenario analysis. "These new probabilities reflect our view that while Tesla's balance sheet should be able to withstand a highly disruptive Q2, the risk of an extended shutdown at Fremont could put significant pressure on the balance sheet (we assume minimum cash of around $2.0 billion)," he wrote. Michaeli also worries that some of the U.S. regions that have seen the biggest COVID-19 impacts are "significant [electric-vehicle] sales contributors," which in his view "calls into question the pace of demand even if Fremont were to restart production." Michaeli has a sell rating on Tesla shares, which are up some 6% in premarket trading Tuesday. The stock has dropped 48% over the past month as the S&P 500 has fallen 31%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

March 24, 2020 08:07 ET (12:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.